Why ResMed (RMD) Narrative Is Shifting As Analysts Reassess Growth And Valuation Assumptions

AI summary

ResMed’s fair value estimate has been trimmed from US$296.53 to US$288.21, a reduction of about 2.8% that signals a more cautious stance on what analysts are willing to pay for the shares. This shift lines up with recent research where some firms have cut price targets by US$5 to US$45, while others still see room to build exposure based on their own assumptions. As you read on, you will see how to interpret these mixed signals and keep track of how the story around ResMed is...